EE05110B1 - 3-(3-isopropl-5-metl-4H-1,2,4-triasool-4-l)ekso-8-asabitsklo[3.2.1]oktaani derivaadid, selliste derivaatide valmistamismeetodid, nende valmistamisel kasutatavad vahehendid, selliseid derivaatesisaldavad kompositsioonid ja kombinatsioonid ning - Google Patents
3-(3-isopropl-5-metl-4H-1,2,4-triasool-4-l)ekso-8-asabitsklo[3.2.1]oktaani derivaadid, selliste derivaatide valmistamismeetodid, nende valmistamisel kasutatavad vahehendid, selliseid derivaatesisaldavad kompositsioonid ja kombinatsioonid ningInfo
- Publication number
- EE05110B1 EE05110B1 EEP200200656A EEP200200656A EE05110B1 EE 05110 B1 EE05110 B1 EE 05110B1 EE P200200656 A EEP200200656 A EE P200200656A EE P200200656 A EEP200200656 A EE P200200656A EE 05110 B1 EE05110 B1 EE 05110B1
- Authority
- EE
- Estonia
- Prior art keywords
- derivatives
- preparation
- azabicyclo
- exo
- triazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0014046A GB0014046D0 (en) | 2000-05-26 | 2000-05-26 | Compounds useful in therapy |
| GB0015835A GB0015835D0 (en) | 2000-06-27 | 2000-06-27 | Compounds useful in therapy |
| PCT/IB2001/000806 WO2001090106A2 (en) | 2000-05-26 | 2001-05-09 | Tryasolyl tropane derivatives as ccr5 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EE200200656A EE200200656A (et) | 2004-06-15 |
| EE05110B1 true EE05110B1 (et) | 2008-12-15 |
Family
ID=26244452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200200656A EE05110B1 (et) | 2000-05-26 | 2001-05-09 | 3-(3-isopropl-5-metl-4H-1,2,4-triasool-4-l)ekso-8-asabitsklo[3.2.1]oktaani derivaadid, selliste derivaatide valmistamismeetodid, nende valmistamisel kasutatavad vahehendid, selliseid derivaatesisaldavad kompositsioonid ja kombinatsioonid ning |
Country Status (50)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA007580B1 (ru) * | 2000-05-26 | 2006-12-29 | Пфайзер Инк. | Комбинация, содержащая производные тропана, полезные в терапии |
| KR20040007672A (ko) * | 2001-06-12 | 2004-01-24 | 에스케이 주식회사 | 신규한 페닐알킬디아민 및 아미드 유사체 |
| SE0103818D0 (sv) | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| SE0200919D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Chemical compounds |
| US6855724B2 (en) | 2002-04-08 | 2005-02-15 | Agouron Pharmaceuticals, Inc. | Tropane derivatives useful in therapy |
| PL372968A1 (en) * | 2002-04-08 | 2005-08-08 | Pfizer Inc. | Tropane derivatives as ccr5 modulators |
| GB0208071D0 (en) * | 2002-04-08 | 2002-05-22 | Pfizer Ltd | Tropane derivatives useful in therapy |
| MXPA04011577A (es) * | 2002-05-23 | 2005-03-07 | Pfizer | Metodo para la identificacion de un ligando, por el cual se mide el tiempo de residencia del receptor. |
| JP2006514646A (ja) * | 2002-12-13 | 2006-05-11 | スミスクライン ビーチャム コーポレーション | Ｃｃｒ５アンタゴニストとしてのシクロヘキシル化合物類 |
| SE0301369D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Chemical compounds |
| DE10336274A1 (de) * | 2003-08-07 | 2005-03-10 | Honeywell Specialty Chemicals | Verfahren zur Herstellung von geminalen Difluoralkanen |
| EP1663999A2 (en) | 2003-08-29 | 2006-06-07 | Ranbaxy Laboratories, Ltd. | Inhibitors of phosphodiesterase type-iv |
| CA2579609A1 (en) | 2003-09-10 | 2005-03-17 | Virochem Pharma Inc. | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity |
| RS20060198A (en) * | 2003-10-03 | 2008-09-29 | Pfizer Limited, | Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activ ity for the treatment of hiv and inflammation |
| TW200610761A (en) * | 2004-04-23 | 2006-04-01 | Astrazeneca Ab | Chemical compounds |
| PL1761542T3 (pl) | 2004-06-09 | 2008-06-30 | Hoffmann La Roche | Pochodne oktahydropirolo[3,4-c]pirolu i ich zastosowanie jako środków przeciwwirusowych |
| EP1814549A2 (en) * | 2004-11-19 | 2007-08-08 | Boehringer Ingelheim International GmbH | Method for treating hiv infection through co-administration of tipranavir and uk-427, 857 |
| WO2006064340A2 (en) * | 2004-12-13 | 2006-06-22 | Pfizer Limited | Process for the preparation of n-acyl beta-aminoaldehydes |
| US7665658B2 (en) | 2005-06-07 | 2010-02-23 | First Data Corporation | Dynamic aggregation of payment transactions |
| WO2007014114A2 (en) | 2005-07-22 | 2007-02-01 | Progenics Pharmaceuticals, Inc. | Methods for reducing viral load in hiv-1-infected patients |
| CN101291905A (zh) | 2005-10-19 | 2008-10-22 | 弗·哈夫曼-拉罗切有限公司 | 苯乙酰胺nnrt抑制剂 |
| KR20090013827A (ko) * | 2006-06-12 | 2009-02-05 | 화이자 프로덕츠 인크. | Ｈｉｖ 환자에서 면역 재구성을 증진시키고 기회 감염을 치료하기 위한 ｃｃｒ５ 길항제 |
| BRPI0715193A2 (pt) | 2006-08-16 | 2013-10-01 | Hoffmann La Roche | inibidores nço-nucleosÍdicos da transcriptase reversa |
| WO2008063600A2 (en) * | 2006-11-17 | 2008-05-29 | Concert Pharmaceuticals Inc. | Triazolyl tropane derivatives |
| ES2550152T3 (es) | 2006-12-13 | 2015-11-04 | F. Hoffmann-La Roche Ag | Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa |
| CA2673566A1 (en) * | 2006-12-19 | 2008-06-26 | Auspex Pharmaceuticals, Inc. | Preparation and utility of ccr5 inhibitors |
| EP1958947A1 (en) | 2007-02-15 | 2008-08-20 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type 4 |
| WO2008132128A2 (en) * | 2007-04-27 | 2008-11-06 | Solvay (Société Anonyme) | Synthesis of a pharmaceutically active compound |
| RU2368613C1 (ru) * | 2008-02-19 | 2009-09-27 | Институт молекулярной генетики Российской Академии наук (ИМГ РАН) (Статус Государственного учреждения) | Равномерно меченный тритием 4,4-дифтор-n-{(1s)-3-[3-(3-изопропил-5-метил-4н-1,2,4-триазол-4-ил)-8-азабицикло[3.2.1]окт-8-ил]-1-фенилпропил}циклогексан карбодиимид |
| WO2009111218A2 (en) * | 2008-02-29 | 2009-09-11 | Schering Corporation | Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same |
| CN101712679B (zh) | 2008-10-08 | 2013-04-10 | 中国科学院上海药物研究所 | 一种酰胺类化合物、其药物组合物及其制备方法和用途 |
| WO2011011652A1 (en) * | 2009-07-24 | 2011-01-27 | Glaxosmithkline Llc | Therapeutic compounds |
| CN102140104B (zh) * | 2010-02-03 | 2014-11-12 | 中国科学院上海药物研究所 | 1-(3-(s)-氨基丙基)-哌啶-4-氨基酰胺类化合物、其药物组合物及其制备方法和用途 |
| EP2552429A1 (en) | 2010-04-02 | 2013-02-06 | Phivco-1 LLC | Combination therapy comprising a ccr5 antagonist, a hiv-1 protease inhibitor and a pharmacokinetic enhancer |
| CN106977511B (zh) * | 2011-12-19 | 2019-04-12 | 中国科学院上海药物研究所 | 一种氨基丙基取代托烷胺类化合物、其药物组合物及其制备方法和用途 |
| EP2912047B1 (en) | 2012-10-29 | 2016-08-24 | Cipla Limited | Antiviral phosphonate analogues and process for preparation thereof |
| CZ306455B6 (cs) | 2013-04-26 | 2017-02-01 | Zentiva, K.S. | Nový způsob syntézy Maravirocu |
| CN103497164B (zh) * | 2013-09-23 | 2015-12-23 | 西安近代化学研究所 | 一种蒽衍生物及其制备方法 |
| CN104304248B (zh) * | 2014-10-23 | 2016-08-10 | 西北农林科技大学 | 3-芳基丙酸酯类化合物作为制备杀螨药物的应用 |
| CN104402883B (zh) * | 2014-10-24 | 2016-04-27 | 艾琪康医药科技（上海）有限公司 | 4，4-二氟金刚烷甲酰胺衍生物、药物组合物及其制备方法和用途 |
| CN104387379B (zh) * | 2014-11-26 | 2017-01-11 | 扬州氟药科技有限公司 | 一种二氟亚甲基哌啶甲酰胺衍生物及其制备方法和用途 |
| CN104860946A (zh) * | 2015-05-14 | 2015-08-26 | 湖北生物医药产业技术研究院有限公司 | Ccr5拮抗剂的制备方法 |
| CN107879963A (zh) | 2016-09-29 | 2018-04-06 | 中国科学院上海药物研究所 | 新型手性配体、金属螯合物、多种非天然氨基酸、马拉维诺及其关键中间体的合成方法 |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5648511A (en) * | 1990-11-19 | 1997-07-15 | G.D. Searle & Co. | Method for making intermediates useful in the synthesis of retroviral protease inhibitors |
| FR2676444B1 (fr) * | 1991-05-16 | 1995-03-10 | Sanofi Elf | Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant. |
| GB9310713D0 (en) * | 1993-05-24 | 1993-07-07 | Zeneca Ltd | Aryl substituted heterocycles |
| PL183025B1 (pl) * | 1994-04-19 | 2002-05-31 | Neurosearch As | Pochodne tropanu, sposób ich otrzymywania i zawierające je kompozycje |
| GB9523526D0 (en) * | 1995-11-17 | 1996-01-17 | Zeneca Ltd | Therapeutic compounds |
| DE19546462A1 (de) * | 1995-12-13 | 1997-06-19 | Bayer Ag | Diarylacetylenketone |
| AU1208397A (en) * | 1995-12-28 | 1997-07-28 | Takeda Chemical Industries Ltd. | Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists |
| US6323206B1 (en) * | 1996-07-12 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| WO1998002151A2 (en) * | 1996-07-12 | 1998-01-22 | Leukosite, Inc. | Chemokine receptor antagonists and methods of use therefor |
| WO1998025617A1 (en) * | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| WO1998025604A1 (en) * | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| CA2296314A1 (en) * | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| IL125658A0 (en) * | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| AR013669A1 (es) * | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
| CA2318088A1 (en) * | 1998-01-21 | 1999-07-29 | Yoshisuke Nakasato | Chemokine receptor antagonists and methods of use therefor |
| US7217714B1 (en) * | 1998-12-23 | 2007-05-15 | Agouron Pharmaceuticals, Inc. | CCR5 modulators |
| PE20001420A1 (es) * | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
| EP1013276A1 (en) | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
| EA007580B1 (ru) * | 2000-05-26 | 2006-12-29 | Пфайзер Инк. | Комбинация, содержащая производные тропана, полезные в терапии |
-
2001
- 2001-05-09 EA EA200401056A patent/EA007580B1/ru not_active IP Right Cessation
- 2001-05-09 CA CA 2408909 patent/CA2408909C/en not_active Expired - Lifetime
- 2001-05-09 OA OA1200200343A patent/OA12264A/en unknown
- 2001-05-09 RS RSP-2009/0438A patent/RS51436B/en unknown
- 2001-05-09 CN CNB018088287A patent/CN1279040C/zh not_active Expired - Lifetime
- 2001-05-09 ES ES04004193T patent/ES2311126T3/es not_active Expired - Lifetime
- 2001-05-09 SI SI200130862T patent/SI1526134T1/sl unknown
- 2001-05-09 EE EEP200200656A patent/EE05110B1/xx active Protection Beyond IP Right Term
- 2001-05-09 PL PL359267A patent/PL200551B1/pl unknown
- 2001-05-09 AT AT01925808T patent/ATE260914T1/de active
- 2001-05-09 MX MXPA02011631A patent/MXPA02011631A/es active IP Right Grant
- 2001-05-09 IL IL15253101A patent/IL152531A0/xx unknown
- 2001-05-09 AT AT04004193T patent/ATE407134T1/de active
- 2001-05-09 JP JP2001586293A patent/JP3693957B2/ja not_active Expired - Lifetime
- 2001-05-09 DK DK04004193T patent/DK1526134T3/da active
- 2001-05-09 DK DK01925808T patent/DK1284974T3/da active
- 2001-05-09 PT PT01925808T patent/PT1284974E/pt unknown
- 2001-05-09 RS YUP82202 patent/RS50904B/sr unknown
- 2001-05-09 AU AU5248201A patent/AU5248201A/xx active Pending
- 2001-05-09 NZ NZ521477A patent/NZ521477A/en not_active IP Right Cessation
- 2001-05-09 BR BRPI0110955A patent/BRPI0110955B8/pt not_active IP Right Cessation
- 2001-05-09 DE DE60135685T patent/DE60135685D1/de not_active Expired - Lifetime
- 2001-05-09 HU HU0302474A patent/HU225810B1/hu active Protection Beyond IP Right Term
- 2001-05-09 EP EP20080163025 patent/EP1990341B1/en not_active Expired - Lifetime
- 2001-05-09 AU AU2001252482A patent/AU2001252482B2/en not_active Expired
- 2001-05-09 KR KR10-2002-7015934A patent/KR100523501B1/ko not_active Expired - Lifetime
- 2001-05-09 EP EP20010925808 patent/EP1284974B1/en not_active Expired - Lifetime
- 2001-05-09 CN CNB2005100068151A patent/CN100355753C/zh not_active Expired - Lifetime
- 2001-05-09 SI SI200130090T patent/SI1284974T1/xx unknown
- 2001-05-09 HR HR20020938A patent/HRP20020938B1/xx not_active IP Right Cessation
- 2001-05-09 EP EP20040004193 patent/EP1526134B1/en not_active Expired - Lifetime
- 2001-05-09 WO PCT/IB2001/000806 patent/WO2001090106A2/en active IP Right Grant
- 2001-05-09 ES ES08163025T patent/ES2401812T3/es not_active Expired - Lifetime
- 2001-05-09 DE DE200812000011 patent/DE122008000011I1/de active Pending
- 2001-05-09 EA EA200201141A patent/EA005382B1/ru not_active IP Right Cessation
- 2001-05-09 CZ CZ20023806A patent/CZ299102B6/cs not_active IP Right Cessation
- 2001-05-09 TR TR200400541T patent/TR200400541T4/xx unknown
- 2001-05-09 DE DE2001602233 patent/DE60102233T2/de not_active Expired - Lifetime
- 2001-05-09 PT PT04004193T patent/PT1526134E/pt unknown
- 2001-05-09 GE GEAP2001004960 patent/GEP20063799B/en unknown
- 2001-05-09 ME MEP-693/08A patent/ME00555A/xx unknown
- 2001-05-09 DZ DZ013464A patent/DZ3464A1/fr active
- 2001-05-09 AP APAP/P/2002/002663A patent/AP1965A/en active
- 2001-05-09 SK SK1643-2002A patent/SK286129B6/sk active Protection Beyond IP Right Term
- 2001-05-09 KR KR1020057003492A patent/KR100548854B1/ko not_active Expired - Lifetime
- 2001-05-09 ES ES01925808T patent/ES2215129T3/es not_active Expired - Lifetime
- 2001-05-21 TW TW90112055A patent/TWI230160B/zh not_active IP Right Cessation
- 2001-05-22 EG EG20010535A patent/EG24137A/xx active
- 2001-05-22 PA PA8517101A patent/PA8517101A1/es unknown
- 2001-05-23 MY MYPI20094132A patent/MY156920A/en unknown
- 2001-05-23 MY MYPI20012461 patent/MY131019A/en unknown
- 2001-05-23 MY MYPI20041980 patent/MY153023A/en unknown
- 2001-05-24 PE PE2001000476A patent/PE20011371A1/es active IP Right Grant
- 2001-05-24 UY UY26727A patent/UY26727A1/es not_active IP Right Cessation
- 2001-05-24 AR ARP010102486 patent/AR028622A1/es active IP Right Grant
- 2001-05-25 TN TNSN01077 patent/TNSN01077A1/fr unknown
-
2002
- 2002-09-23 BG BG107140A patent/BG65966B1/bg unknown
- 2002-09-24 IS IS6565A patent/IS2511B/is unknown
- 2002-10-28 IL IL152531A patent/IL152531A/en active Protection Beyond IP Right Term
- 2002-10-28 CU CU20020243A patent/CU23288B7/es unknown
- 2002-10-31 NO NO20025227A patent/NO327892B1/no not_active IP Right Cessation
- 2002-11-14 MA MA26910A patent/MA26902A1/fr unknown
-
2005
- 2005-02-15 JP JP2005038062A patent/JP4854970B2/ja not_active Expired - Lifetime
-
2007
- 2007-03-27 AR ARP070101273 patent/AR060159A2/es unknown
-
2008
- 2008-02-22 LU LU91417C patent/LU91417I2/fr unknown
- 2008-02-22 NL NL300338C patent/NL300338I2/nl unknown
- 2008-02-25 LT LTPA2008004C patent/LTC1284974I2/lt unknown
- 2008-03-04 FR FR08C0007C patent/FR08C0007I2/fr active Active
- 2008-03-17 CY CY200800006C patent/CY2008006I2/el unknown
- 2008-07-16 CR CR10145A patent/CR10145A/es unknown
- 2008-10-24 CY CY081101203T patent/CY1108451T1/el unknown
-
2010
- 2010-04-08 NO NO2010007C patent/NO2010007I2/no unknown
-
2020
- 2020-06-30 NO NO2020019C patent/NO2020019I1/no not_active IP Right Cessation
-
2022
- 2022-04-19 CY CY2022009C patent/CY2022009I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE05110B1 (et) | 3-(3-isopropl-5-metl-4H-1,2,4-triasool-4-l)ekso-8-asabitsklo[3.2.1]oktaani derivaadid, selliste derivaatide valmistamismeetodid, nende valmistamisel kasutatavad vahehendid, selliseid derivaatesisaldavad kompositsioonid ja kombinatsioonid ning | |
| AU2001276048A1 (en) | Rapid-melt semi-solid compositions, methods of making same and methods of using same | |
| AU2001279284A1 (en) | Rapid-melt semi-solid compositions, methods of making same and methods of using same | |
| FR2810033B1 (fr) | Nouveaux composes de la famille des n-acylamino-amides, compositions les comprenant, et utilisations | |
| BE2015C026I2 (en) | 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens | |
| EE05081B1 (et) | Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid | |
| EE200300151A (et) | Ravimitena kasutatavad antikolinergikumid ning meetodid nende valmistamiseks | |
| EE05104B1 (et) | Asetidiini derivaadid, nende valmistamise meetodid ja farmatseutiline kompositsioon | |
| EE200200470A (et) | Uued ühendid, meetod nende valmistamiseks ning nende kasutamine | |
| EE200300207A (et) | Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon | |
| HUP9802822A3 (en) | Halobenzimidazol derivatives, intermediates, preparation thereof and microbocide compositions containing these compounds as active ingredients | |
| AU2001241474A1 (en) | Biosensor compositions and methods of use | |
| IL154981A0 (en) | Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppay-y-binding agents | |
| WO2004096798A3 (fr) | Derives de 2-acylamino-4-phenylthiazole, leur preparation et leur application en therapeutique | |
| HUP0203836A3 (en) | 1,3-disubstituted pyrrololidines as alpha-2-adrenoceptor antagonists, process for their preparation and pharmaceutical compositions containing them and their use | |
| AU2001235737A1 (en) | Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same | |
| EE04917B1 (et) | Antihistamiinsed spirohendid, vahehendid ja farmatseutiline kompositsioon ning nende valmistamismeetodid ja kasutamine | |
| EE04717B1 (et) | Indolüülpiperidiinühendid, nende valmistamismeetod, kompositsioon ja nende kasutamine | |
| WO2002041881A3 (de) | Repinotan-kit | |
| HUP0204563A3 (en) | Process for preparation of 3,3-diarylpropylamine derivatives and their intermediates and their use for preparation of pharmaceutical compositions | |
| HUP0204354A3 (en) | Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same and their use | |
| EE200000767A (et) | Asendatud triasolopüridasiini derivaat, selle valmistamismeetod ja kasutamine ning farmatseutiline kompositsioon | |
| HUP0300127A3 (en) | Nematicidal trifluorobutene-derivatives, their preparation, the novel intermediates composition containing the same and use thereof | |
| EE200000099A (et) | Antimükootiline kompositsioon, selle kasutamine ja valmistamismeetod ning antimükootiline toode | |
| AU2002218322A1 (en) | Substituted cyclohexenes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB4A | Valid patent at the end of a year |
Effective date: 20081231 |
|
| AA1Y | Spc filed |
Free format text: PRODUCT NAME: CELSENTRI-MARAVIROC Spc suppl protection certif: C20090002 Filing date: 20090529 |
|
| FG1Y | Spc granted |
Free format text: PRODUCT NAME: CELSENTRI-MARAVIROC Spc suppl protection certif: C20090002 00023 Filing date: 20090529 Extension date: 20220918 |
|
| KB4A | Valid patent at the end of a year |
Effective date: 20101231 |
|
| HC1A | Change of owner name | ||
| SPCM | Correction and amendment to the data concerning application for a supplementary protection certificate |
Spc suppl protection certif: C20090002 00023 Extension date: 20220920 |
|
| GB1A | Change in the ownership or in the address of the owner | ||
| SPCZ | Extension of supplementary protection certificate: granted [paediatric extension] |
Free format text: PRODUCT NAME: MARAVIROC; NATIONAL AUTHORISATION NUMBER: EMA/253407/2017; DATE OF AUTHORISATION: 20170421 Spc suppl protection certif: C20090002 Extension date: 20230318 |